Myriad Genetics, Inc. (MYGN) may issue up to $200 million worth of common stock, preferred stock, depositary shares, debt securities, and warrants. This prospectus provides a general description of these securities, with specific terms detailed in future prospectus supplements. The company, a leader in molecular diagnostics and precision medicine, develops and commercialize tests that assess disease risk and guide treatment decisions. Its growth strategy focuses on expanding its testing portfolio and integrating precision medicine solutions into clinical workflows, particularly in cancer care, prenatal health, and mental health. The prospectus highlights risks such as declining test sales, competition, regulatory changes, and technological advancements. Proceeds from the offering will be used for general corporate purposes, including operations, R&D, new product development, debt repayment, and potential acquisitions. The company's common stock is listed on Nasdaq under the symbol MYGN, and its financial statements have been audited by Ernst & Young LLP. Additional information is available in the company's SEC filings and on its website.
